SL BIGEN - Crunchbase Company Profile & Funding

Q: Where is SL BIGEN's headquarters?

SL BIGEN is located in Seongnam, Kyonggi-do, South Korea.

Q: Who invested in SL BIGEN?

SL BIGEN is funded by Yuhan Corporation.

Q: When was the last funding round for SL BIGEN?

SL BIGEN closed its last funding round on obfuscated from a Corporate Round round.

Q: How much funding has SL BIGEN raised to date?

SL BIGEN has raised obfuscated.

Overview

SL BIGEN

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About SL BIGEN

CB Rank

151886

SL BIGEN is a R&D-oriented company that develops therapeutics for cancer and neurodegenerative diseases.

Founded

obfuscation

Private

Corporate Round

Seongnam, Kyonggi-do, South Korea

11-50

slbigen.com/

Product Research

Funding Rounds

Corporate Round

OBF

obfuscation

Key People

Saewon Kim: Chief Research Scientist
Hyun-Tak Jin: CEO

Details

Legal Name

SL BIGEN. Co., Ltd.

Operating Status

Active

Number of Exits

obfuscation

Company Type

For Profit

Founders

Youngchul Sung

About the Company

SL BIGEN is a research and development business that aims to save patients' lives through bio-genetic engineering. SL BIGEN is working on two projects: I a first-in-class mesenchymal stem cell line engineered to express disease-specific therapeutic genes, and (ii) a multi-engineered natural killer cell line expressing fourth generation

chimeric antigen receptors. Cancer and neurological illnesses are among the therapeutic areas covered by the company.

Phone Number

031-628-2188

Contact Email

admin@slbigen.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round
obfuscated obfuscation	Corporate Round - SL BIGEN	1	obfuscated obfuscation	Yuhan Corporation	Corporate Round

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Yuhan Corporation	Yes	Corporate Round - SL BIGEN	—
Yuhan Corporation	Yes	Corporate Round - SL BIGEN	—
Yuhan Corporation	Yes	Corporate Round - SL BIGEN	—
Yuhan Corporation	Yes	Corporate Round - SL BIGEN	—
Yuhan Corporation	Yes	Corporate Round - SL BIGEN	—

Investments

Investment Breakdown

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation

Investment Breakdown

Number of Investments

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation
obfuscated obfuscation	Progen	—	Post-IPO Equity - Progen	obfuscated obfuscation